Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, Potter V, Koh MB, Islam MS, Russell N, Marks DI, Mufti GJ, Pagliuca A. Marsh JC, et al. Among authors: lim z. Blood. 2011 Aug 25;118(8):2351-7. doi: 10.1182/blood-2010-12-327536. Epub 2011 Apr 25. Blood. 2011. PMID: 21518925 Free article. Clinical Trial.
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ. Krishnamurthy P, et al. Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21. Biol Blood Marrow Transplant. 2013. PMID: 23266740 Free article.
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.
Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ. Potter VT, et al. Among authors: lim z. Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8. Biol Blood Marrow Transplant. 2014. PMID: 24216184 Free article.
Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.
Marsh JC, Pearce RM, Koh MB, Lim Z, Pagliuca A, Mufti GJ, Perry J, Snowden JA, Vora AJ, Wynn RT, Russell N, Gibson B, Gilleece M, Milligan D, Veys P, Samarasinghe S, McMullin M, Kirkland K, Cook G; British Society for Blood and Marrow Transplantation, Clinical Trials Committee. Marsh JC, et al. Among authors: lim z. Bone Marrow Transplant. 2014 Jan;49(1):42-8. doi: 10.1038/bmt.2013.115. Epub 2013 Aug 5. Bone Marrow Transplant. 2014. PMID: 23912664
Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, Tobal K, Devereux S, Pagliuca A, Mufti GJ. Lim ZY, et al. Br J Haematol. 2007 Aug;138(4):517-26. doi: 10.1111/j.1365-2141.2007.06676.x. Epub 2007 Jun 29. Br J Haematol. 2007. PMID: 17608767 Free article.
581 results